Clinical Trials Browser

Completed × OTHER × trametinib × Clear all

NCT02645149 2026-05-29

Match Mel

Phase 2 Completed

Melanoma

NCT03244956 2026-03-23

MERAIODE

Phase 2 Completed

EndocrineHead & Neck

Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation

NCT03501368 2026-02-27

Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma

Phase 1 Completed

Melanoma

NCT01723202 2025-08-24

Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer

Phase 2 Completed

53 enrolled 11 charts

EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT02230553 2025-07-08

M14LTK

Phase 1/2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT05440942 2025-06-05

Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma

Phase 1 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT03299088 2025-05-21

Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations

Phase 1 Completed

15 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung

NCT03704688 2025-05-16

Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer

Phase 1/2 Completed

12 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT04487106 2025-04-22

Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

Phase 2 Completed

21 enrolled 14 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03026517 2025-01-23

Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma

Phase 1 Completed

Melanoma

NCT02872259 2025-01-14

BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma

Phase 1/2 Completed

Melanoma

NCT02392871 2024-11-27

CombiRT

Phase 1/2 Completed

Melanoma

NCT03455764 2024-07-31

MCS110 With BRAF/MEK Inhibition in Patients With Melanoma

Phase 1/2 Completed

6 enrolled 12 charts

Melanoma

NCT03434262 2024-05-31

SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors

Phase 1 Completed

Choroid Plexus Carcinoma, Microphthalmia, Isolated, with Coloboma 5, Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Lymphoma, Follicular, Medulloblastoma, Meningioma, Neoplasms, Neoplasms, Germ Cell and Embryonal, Oligodendroglioma, Pinealoma, Recurrence, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Neoplasms, Neuroepithelial, Rhabdoid Tumor, Pyloric Stenosis, Hypertrophic

NCT04967079 2024-04-23

Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT03317119 2024-04-08

Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery

Phase 1 Completed

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT03076164 2024-04-02

A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib

Phase 1/2 Completed

24 enrolled 8 charts

Adenocarcinoma of Lung, Lung Neoplasms

NCT03516214 2024-02-15

EATON

Phase 1 Completed

Bronchial Neoplasms

NCT02367859 2024-01-30

Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma

Phase 2 Completed

1 enrolled 5 charts

Ameloblastoma, Adamantinoma

NCT04059224 2023-09-26

TraMel-WT

Phase 2 Completed

Melanoma

NCT01740648 2023-09-18

Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer

Phase 1 Completed

Gastrointestinal

Rectal Neoplasms

NCT03714958 2023-09-13

TRAHD

Phase 1 Completed

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT03428126 2023-06-15

Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer

Phase 2 Completed

29 enrolled 9 charts

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT02428270 2022-11-01

A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer

Phase 2 Completed

Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

NCT02399943 2022-05-16

A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer

Phase 2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT02292173 2021-06-10

Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer

Phase 1 Completed

Gastrointestinal

Digestive System Diseases, Liver Diseases, Liver Neoplasms

NCT02296112 2021-05-28

Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations

Phase 2 Completed

9 enrolled 14 charts

Melanoma

NCT03352947 2020-12-08

INTERIM

Phase 2 Completed

Melanoma

NCT01467310 2020-09-02

Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212

Phase EARLY_PHASE1 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01941927 2020-02-12

Trametinib With GSK2141795 in BRAF Wild-type Melanoma

Phase 2 Completed

20 enrolled 16 charts

Melanoma

NCT02439411 2019-12-02

DEIS

Melanoma

NCT02296996 2019-01-23

Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients

Phase 2 Completed

Melanoma

NCT01438554 2018-08-29

Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma

Phase 1 Completed

GastrointestinalHead & NeckSarcoma

Sarcoma, Thyroid Neoplasms, Cholangiocarcinoma

NCT02138292 2018-05-15

A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma

Phase 1 Completed

Melanoma

NCT01553851 2016-12-26

GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer

Phase 2 Completed

20 enrolled 13 charts

Mouth Neoplasms

NCT01619774 2016-12-12

An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor

Phase 2 Completed

28 enrolled 7 charts

Melanoma